Protective effect of magnesium isoglycyrrhizinate on the liver of hepatic arterial chemoembolization

Objective To investigate the protective effect of magnesium isoglycyrrhizinate on the liver of hepatic arterial chemoembolization. Methods 68 patients with hepatic arterial chemoembolization were selected as research subjects, they were divided into magnesium isoglycyrrhizinate group and control group.All patients were routinely given hepatoprotective drug treatment from seven days before surgery until three days after surgery, magnesium isoglycyrrhizinate group was given magnesium isoglycyrrhizinate treatment on the basis of hepatoprotective treatment.Detected and compared the alanine aminotransferase, aspartate aminotransferase, total bilirubin, total protein, albumin and cholinesterase levels before and after liver cancer before and after surgery. Results The alanine aminotransferase, aspartate aminotransferase levels at 3 days after surgery[(60.2±25.8) and (71.5±29.6)IU/L]were higher than before surgery in the control group[(34.7±18.6) and (49.5±20.4)IU/L](t=7.264 and 5.974, all P 0.05). The alanine aminotransferase, aspartate aminotransferase and total bilirubin levels before surgery in magnesium isoglycyrrhizinate group had no differences with the control group (P>0.05). The alanine aminotransferase, aspartate aminotransferase levels at 3 days after surgery in the magnesium isoglycyrrhizinate group[(44.8±22.8) and (57.3±24.8)IU/L]were higher than those in the control group[(60.2±25.8) and (71.5±29.6)IU/L](t=6.385 and 7.358, all P 0.05). The albumin and cholinesterase levels at 3 days after surgery in the magnesium isoglycyrrhizinate group[(28.4±4.7)g/L, (8.0±4.8)kU/L]were lower than those of control group[(29.3±3.5)g/L, (6.9±4.3)kU/L](t=8.436 and 6.947, all P<0.05). The incidence rates of adverse reactions of the magnesium isoglycyrrhizinate group (upper abdominal pain incidence rate was 35.3%, fever incidence rate was 29.4%, nausea and vomiting incidence rate was 52.9%) were lower than those of the control group(55.9%, 88.2%, 76.5%)(χ2=7.246, 6.472, 6.274, all P<0.05). Conclusion Hepatic arterial chemoembolization has some damage to liver function of liver cancer patients.Magnesium isoglycyrrhizinate can reduce liver damage, improve liver synthetic function, and has a protective effect on liver. Key words: Magnesium isoglycyrrhizinate; Primary liver cancer; Transcatheter arterial chemoembolization; Hepatic function